Results 221 to 230 of about 101,843 (265)
Some of the next articles are maybe not open access.
Monoclonal antibodies in myeloma.
Clinical advances in hematology & oncology : H&O, 2015The development of monoclonal antibodies (mAbs) for the treatment of disease goes back to the vision of Paul Ehrlich in the late 19th century; however, the first successful treatment with a mAb was not until 1982, in a lymphoma patient. In multiple myeloma, mAbs are a very recent and exciting addition to the therapeutic armamentarium. The incorporation
Sondergeld, P.+3 more
openaire +4 more sources
International Journal of Radiation Oncology*Biology*Physics, 1989
M D, Melamed, C E, Bradley
+6 more sources
M D, Melamed, C E, Bradley
+6 more sources
An Overview of Monoclonal Antibodies
Seminars in Oncology Nursing, 2019To provide a brief overview of the development of monoclonal antibodies in immunotherapy, including a review of the mechanism of action and types, and indications for use.Peer-reviewed journal articles, book chapters, internet.Monoclonal antibodies offer alternative treatment to cancer patients who have failed or progressed on standard chemotherapy ...
openaire +2 more sources
Monoclonal antibodies to prothrombin
Thrombosis Research, 1987Hybridoma technology was used for the production of murine monoclonal antibodies to bovine normal prothrombin. Hybrid cell cultures were assayed for the production of antibodies, both in the absence and presence of calcium ions, by Enzyme-Linked Immunosorbent Assay (ELISA). Antibody-producing cell lines were cloned two times and grown as ascites tumors.
Oscar Sudilovsky, Om P. Malhotra
openaire +3 more sources
Molecular and Cellular Biochemistry, 1984
The technology for the production of murine monoclonal antibodies has been refined enormously since its introduction in 1975. However, the technology for generating human monoclonal antibodies has only recently come into its own. In this review, three currently available approaches to the production of human monoclonal antibodies are described.
D. Kozbor+4 more
openaire +3 more sources
The technology for the production of murine monoclonal antibodies has been refined enormously since its introduction in 1975. However, the technology for generating human monoclonal antibodies has only recently come into its own. In this review, three currently available approaches to the production of human monoclonal antibodies are described.
D. Kozbor+4 more
openaire +3 more sources
Deimmunization of Monoclonal Antibodies
2008Immunogenicity is a major limitation to therapy with certain monoclonal antibodies and proteins. A major driver for immunogenicity is the presence of human T-cell epitopes within the protein sequence which can activate helper T-cells resulting in the sustained production of antibodies and neutralization of the therapeutic effect.
Laura J. Crompton+3 more
openaire +3 more sources
Monoclonal antibodies in haematology
Blood Reviews, 1989The development of methods for the production of monoclonal antibodies is having an important impact in the field of immunohaematology. Four separate areas are implicated. First, there is the use of monoclonal antibodies in blood transfusion, where antibodies within the ABO, Rh, Lewis, P, MN, Kell and Lutheran systems are available.
openaire +3 more sources